MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer

Shoaib Afzal, S. A. Jensen, B. Veiner, Ulla Vogel, J. P. Matsen, J. B. Sørensen, P. K. Andersen, H. E. Poulsen

    Research output: Contribution to journalJournal articleResearchpeer-review


    Patients and methods: We included 331 patients who had been treated with adjuvant 5-FU/leucovorin chemotherapy after intended curative resection between 1997 and 2003. Clinical data, including relapse rates, overall survival, and tumor stage, were collected. DNA was extracted from formalin-fixed tumor tissue and analyzed for the MTHFR 677C > T and 1298A > C SNPs with real-time PCR.

    Results: The MTHFR 677C > T and 1298A > C polymorphisms were not associated with survival or relapse-free survival (P > 0.2). The 677 CC genotype was associated to toxicity (odds ratio = 1.83, P = 0.01).

    Conclusions: The MTHFR 677C > T and 1298A > C polymorphisms probably do not predict efficacy of adjuvant 5-FU treatment in colorectal cancer after complete resection; however, the 677C > T polymorphism may be associated with lower toxicity in 5-FU treatment. Implementation of SNP analysis for these polymorphisms for individualized treatment is premature.

    Original languageEnglish
    JournalAnnals of Oncology
    Issue number10
    Pages (from-to)1660-1666
    Publication statusPublished - 2009


    • colorectal cancer
    • 5-fluorouracil
    • methylenetetrahydrofolate reductase
    • pharmacogenetics
    • single-nucleotide polymorphisms

    Cite this